BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BridgeBio Oncology Therapeutics completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.

Biotechnology

Clinical Trials

Therapeutics

BridgeBio Oncology Therapeutics (BBOT)

BridgeBio Oncology Therapeutics (BBOT)'s headquarters in South San Francisco, United States

Eli Wallace

Pedro J. Beltran

Uneek Mehra

Christine Z. Yang

Angela Peters

Aaron Chan

Idan E.

Howard Chang

The Leadership Team at BridgeBio Oncology Therapeutics is responsible for guiding the strategic direction of the company, ensuring effective drug development and clinical progression of novel therapies targeting RAS and PI3K-driven cancers. This team collaborates across functional areas, including drug discovery, clinical development, and operations, to drive innovation and optimize patient outcomes while managing resources and stakeholder relationships.

Leadership Team

The Clinical Development Team at BridgeBio Oncology Therapeutics is responsible for the design, implementation, and oversight of clinical trials aimed at evaluating the safety and efficacy of novel small molecule therapeutics targeting RAS and PI3K oncogenes. This interdisciplinary team collaborates closely to ensure that the development processes are aligned with regulatory standards, while also focusing on optimizing patient outcomes through innovative clinical strategies. They play a critical role in advancing the company's pipeline from preclinical stages through to clinical proof of concept.

Clinical Development Team

The Legal and Compliance Team at BridgeBio Oncology Therapeutics ensures the company adheres to all regulatory requirements and industry standards while navigating the complex legal landscape of biopharmaceutical development. They provide strategic guidance on contracts, intellectual property, and compliance issues, supporting the company's mission to advance innovative cancer therapies. Additionally, the team collaborates with other departments to mitigate legal risks and promote ethical practices within the organization.

��

BridgeBio Oncology Therapeutics (BBOT)

Org chart

Teams

Leadership Team

Clinical Development Team

Legal and Compliance Team

Offices

��������

BridgeBio Oncology Therapeutics (BBOT)

Org chart

Teams

Leadership Team

Clinical Development Team

Legal and Compliance Team

Offices

Related companies

��